Latest research
Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
Top papers this month · This week's roundup
Trending topics
Phase 2 trial, 71 untreated advanced NSCLC patients: PD-L1-guided sintilimab (alone if PD-L1 ≥50%, plus chemotherapy if <50%) met its primary endpoint (confirmed ORR 51.4%), similar to pembrolizumab; rash was commoner with sintilimab alone.
RCTn = 71
Maggie Liu et al. PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial